Carrizumab

N/A

Report date: 2023/04/25 09:12:29

Base Information

Drug NameCarrizumab
Drug Alias NameCarbarizumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A